Vinkristin etkileşimleri
Vinkristin (Vincasar PFS) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 97 belgelenmiş etkileşim var: 51 majör, 31 orta, 15 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.
Etikete göre etkileşimler
Majör etkileşimler (51)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
- HiyalüronidazMajör
Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis. (Vinkristin etiketi, Kutulu uyarı)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)
Orta düzey etkileşimler (31)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
- DoksorubisinOrta
…treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (Doksorubisin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
…drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged to outweigh… (Gansiklovir etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (Sitarabin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
…associated with myelosuppression or nephrotoxicity (e.g., adriamycin, dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/ sulfamethoxazole, vinblastine, vincristine, and zidovudine) Unknown Because of potential for higher toxicity, coadministration with valganciclovir hydrochloride should be considered only if the potential benefits… (Valgansiklovir etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
- VazopressinOrta
Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (Vazopressin etiketi, İlaç etkileşimleri)
Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (Vinkristin etiketi, İlaç etkileşimleri)
Minör değinmeler (15)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
- BortezomibMinör
…baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12 . (Bortezomib etiketi, Uyarılar ve önlemler)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Concurrent use of strong CYP3A inducers (e.g., St. (Vinkristin etiketi, İlaç etkileşimleri)
Kullandığınız her şeyi Vinkristin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.
Sorgulama aracında açTıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.